Nordson Q3 Sales Jump 12 Percent

Nordson reported strong fiscal Q3 2025 results, with sales up 12% to $742 million and adjusted EPS up 13% to $2.73, alongside record free cash flow of $226 million, representing 180% conversion of net income. This robust cash generation enabled significant debt reduction, lowering net debt by over $100 million and leverage to 2.2x EBITDA, while also supporting an $800 million share repurchase authorization. Growth was primarily driven by 15% organic expansion in the Advanced Technology Solutions (ATS) segment, fueled by demand in electronics dispense products, and early EPS accretion from the Atrion acquisition. Management anticipates full-year 2025 adjusted EPS slightly above the midpoint of guidance, reflecting continued operational execution and margin resilience despite a planned medical business divestiture.

Analysis

Nordson delivered a strong fiscal third-quarter performance, characterized by double-digit growth and exceptional cash generation. Sales increased 12% year-over-year to $742 million, while adjusted EPS rose 13% to $2.73. The standout metric was a record free cash flow of $226 million, representing a 180% conversion rate of net income. This robust cash flow facilitated a significant reduction in net debt by over $100 million sequentially, improving the net debt to EBITDA leverage ratio to 2.2x. This financial discipline is complemented by an aggressive capital return policy, highlighted by a new $800 million share repurchase authorization. Operationally, the Advanced Technology Solutions (ATS) segment was the primary growth engine, with 15% organic growth driven by strong demand in electronics dispense products across Asia-Pacific. The segment also demonstrated significant operating leverage, expanding its EBITDA margin from 21% to 24% on a 42% incremental conversion rate. Furthermore, the strategic acquisition of Atrion proved highly successful, achieving earnings accretion a year ahead of schedule and contributing to a 34% year-over-year EBITDA growth in the Medical and Fluid Solutions segment. Looking forward, management anticipates full-year 2025 adjusted EPS to finish slightly above the midpoint of guidance due to continued operational execution, even as sales are expected to be slightly below the midpoint reflecting a planned business divestiture.

Key Decisions for Investors

• Given the strong top-and-bottom-line growth, record free cash flow, and successful deleveraging, investors should view the company's operational execution and financial discipline favorably.
• Monitor the deployment of the new $800 million share repurchase program and the progress of the Atrion integration, as both are key indicators of management's ability to drive shareholder value through capital allocation and M&A execution.
• While the overall outlook is positive, be mindful of the tougher Q4 year-over-year comparisons for the high-growth ATS segment and the impact of the medical business divestiture on full-year revenue.